Published in Ann Oncol on October 24, 2007
Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. Eur J Nucl Med Mol Imaging (2014) 1.43
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer (2013) 1.43
Positron Emission Tomography (PET) in Oncology. Cancers (Basel) (2014) 1.41
Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound. World J Gastroenterol (2012) 1.15
Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer (2012) 1.13
Methodological considerations in quantification of oncological FDG PET studies. Eur J Nucl Med Mol Imaging (2009) 1.11
Predictive and prognostic value of FDG-PET. Cancer Imaging (2008) 0.96
GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer (2009) 0.92
18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging (2011) 0.92
Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer (2011) 0.88
Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer. Eur J Nucl Med Mol Imaging (2012) 0.84
CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab. Cancer Med (2014) 0.83
Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers. Nat Clin Pract Gastroenterol Hepatol (2009) 0.83
Prognostic significance of (18)FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis. Cancer Imaging (2015) 0.81
The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer. PLoS One (2015) 0.81
Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases. Eur J Nucl Med Mol Imaging (2013) 0.81
FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC. World J Radiol (2014) 0.80
Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer. Oncologist (2014) 0.80
Monitoring of tumor response to Cisplatin using optical spectroscopy. Transl Oncol (2014) 0.79
Correlation between long-term aspirin use and F-fluorodeoxyglucose uptake in colorectal cancer measured by PET/CT. PLoS One (2014) 0.78
PET scans as a predictive marker of survival in advanced colorectal cancer. Clin Colorectal Cancer (2014) 0.77
(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors. World J Nucl Med (2012) 0.77
(18)F-FDG PET/CT quantification in head and neck squamous cell cancer: principles, technical issues and clinical applications. Eur J Nucl Med Mol Imaging (2016) 0.76
Positron Emission Tomography for the Response Evaluation following Treatment with Chemotherapy in Patients Affected by Colorectal Liver Metastases: A Selected Review. Gastroenterol Res Pract (2015) 0.76
Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma. World J Urol (2011) 0.76
Is early response by (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography a predictor of long-term outcome in patients with metastatic colorectal cancer? J Gastrointest Oncol (2016) 0.76
Recent chemotherapy reduces the maximum-standardized uptake value of 18F-fluoro-deoxyglucose positron emission tomography in colorectal cancer. Gut Liver (2014) 0.75
Desmoid tumour (aggressive fibromatosis) of the colon mimics malignancy on dual time-point 18F-FDG PET/CT imaging. Br J Radiol (2012) 0.75
Amplitude-based optimal respiratory gating in positron emission tomography in patients with primary lung cancer. Eur Radiol (2014) 0.75
Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response. World J Surg Oncol (2015) 0.75
Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer. Eur J Nucl Med Mol Imaging (2016) 0.75
Functional imaging biomarkers for assessing response to treatment in liver and lung metastases. Cancer Imaging (2013) 0.75
Evaluation of recurrent disease in the re-staging of colorectal cancer by (18)F-FDG PET/CT: Use of CEA and CA 19-9 in patient selection. Oncol Lett (2016) 0.75
Comparison of Quantitative Methods on FDG PET/CT for Treatment Response Evaluation of Metastatic Colorectal Cancer. Nucl Med Mol Imaging (2016) 0.75
Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib. Eur J Nucl Med Mol Imaging (2016) 0.75
Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med (2012) 15.43
[Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff]. Ned Tijdschr Geneeskd (2005) 5.28
The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ (2006) 3.27
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol (2009) 2.74
Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2008) 2.67
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer (2011) 2.16
Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients. Eur J Radiol (2013) 2.06
Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg (2013) 1.98
Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol (2009) 1.87
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer (2009) 1.75
Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". Eur J Nucl Med Mol Imaging (2007) 1.71
Comment on the use of self-reporting instruments to assess patients with rheumatoid arthritis: the longitudinal association between the DAS28 and the VAS general health. Arthritis Rheum (2006) 1.59
Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol (2002) 1.52
Value of fluorodeoxyglucose positron emission tomography in women with breast cancer. Br J Surg (2005) 1.46
FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology (2008) 1.45
Blistering of the hand in a breast cancer patient. Extravasation. Neth J Med (2011) 1.41
Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci (2009) 1.36
Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol (2008) 1.31
Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol (2012) 1.31
The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer (2010) 1.26
Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs (2008) 1.21
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer (2003) 1.21
Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer (2010) 1.21
F-18-fluorodeoxyglucose positron emission tomography in diagnosis and follow-up of patients with different types of vasculitis. Neth J Med (2003) 1.19
Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM modeling good research practices task force. Value Health (2013) 1.18
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol (2005) 1.17
Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev (2009) 1.14
[Imaging in the diagnosis of colorectal liver metastases and extrahepatic abnormalities]. Ned Tijdschr Geneeskd (2008) 1.10
Development and clinical application of peptide-based radiopharmaceuticals. Curr Pharm Des (2004) 1.10
Radioimmunotherapy and colorectal cancer. Br J Surg (2005) 1.10
FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer (2004) 1.08
Radiolabeled compounds in diagnosis of infectious and inflammatory disease. Curr Pharm Des (2004) 1.08
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer (2008) 1.07
DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer. Ann Oncol (2009) 1.07
Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann Oncol (2006) 1.06
Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother (2008) 1.06
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer (2009) 1.03
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol (2014) 1.03
FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. Ann Oncol (2006) 1.01
Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. Invest New Drugs (2006) 1.00
Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol (2002) 0.99
Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 0.98
Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol (2003) 0.98
Analysis of dendritic cell trafficking using EGFP-transgenic mice. Immunol Lett (2003) 0.98
Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study. Eur J Nucl Med Mol Imaging (2006) 0.98
Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery. Ann Surg Oncol (2006) 0.96
A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br J Cancer (2010) 0.96
Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Ann Oncol (2004) 0.96
Limitations of cytokeratin 20 RT-PCR to detect disseminated tumour cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumour tissue. Mol Pathol (2002) 0.95
A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats. Ann Surg Oncol (2007) 0.94
Aortitis diagnosed by F-18-fluorodeoxyglucose positron emission tomography in a patient with syphilis and HIV coinfection. Infection (2005) 0.94
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). Ann Oncol (2014) 0.93
Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. NMR Biomed (2007) 0.93
Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. Ann Oncol (2010) 0.93
Tailoring therapy in colorectal cancer by PET-CT. Q J Nucl Med Mol Imaging (2009) 0.93
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. Eur J Cancer (2006) 0.93
A prospective study on weight loss and energy intake in patients with head and neck cancer, during diagnosis, treatment and revalidation. Clin Nutr (2006) 0.93
Complicating infectious foci in patients with Staphylococcus aureus or Streptococcus species bacteraemia. Eur J Clin Microbiol Infect Dis (2007) 0.93
FDG-PET for imaging of non-osseous infection and inflammation. Q J Nucl Med Mol Imaging (2006) 0.93
Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array. Br J Cancer (2009) 0.92
Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. Cancer Imaging (2012) 0.92
New targeted probes for radioimaging of angiogenesis. Methods (2009) 0.92
Assessment of mandibular invasion of squamous cell carcinoma by various modes of imaging: constructing a diagnostic algorithm. Int J Oral Maxillofac Surg (2008) 0.92
Corticosteroid-induced osteoporosis: does it occur in patients with Crohn's disease? Am J Gastroenterol (2002) 0.92
131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study. Nucl Med Commun (2002) 0.91
Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg (2006) 0.91
In vivo magnetic resonance spectroscopy of liver tumors and metastases. World J Gastroenterol (2011) 0.90
Validated image fusion of dedicated PET and CT for external beam radiation and therapy in the head and neck area. Q J Nucl Med Mol Imaging (2008) 0.90
Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. Contrast Media Mol Imaging (2014) 0.90
Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol (2005) 0.90
Imaging of infectious diseases using [18F] fluorodeoxyglucose PET. Q J Nucl Med Mol Imaging (2008) 0.89
Long-term global quality of life in patients treated for colorectal liver metastases. Br J Surg (2010) 0.89
Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). Br J Surg (2015) 0.89
Validation of the Care-Related Quality of Life Instrument in different study settings: findings from The Older Persons and Informal Caregivers Survey Minimum DataSet (TOPICS-MDS). Qual Life Res (2014) 0.89
Single-centre experience with tunnelled central venous catheters in 150 cancer patients. Neth J Med (2002) 0.89
The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int (2002) 0.88
Quality of life after surgical treatment of colorectal liver metastases. Br J Surg (2006) 0.88
The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients. HIV Med (2008) 0.88
From anatomical to biological target volumes: the role of PET in radiation treatment planning. Cancer Imaging (2006) 0.87
F-18-fluorodeoxyglucose positron emission tomography leading to a diagnosis of septic thrombophlebitis of the portal vein: description of a case history and review of the literature. J Intern Med (2004) 0.87